You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Automated Systems for Detection and Molecular Characterization of Circulating Tum
SBC: ADVANCED CELL DIAGNOSTICS, INC. Topic: NCIDESCRIPTION (provided by applicant): The detection and enumeration of circulating tumor cells (CTCs) has the potential to become a very powerful tool in cancer diagnosis and treatment. However, current technologies for CTC detection are not yet established in routine clinical practice. One reason is that CTCs are present in blood at an extremely low concentration of one in 10 million white blood c ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Targeted tumoricidal bacteria
SBC: ANTICANCER, INC. Topic: NCIDESCRIPTION (provided by applicant): We have developed an effective bacterial cancer therapy strategy by targeting viable tumor tissue by using Salmonella typhimurium auxotrophs that we have generated which grow in viable as well as necrotic areas of tumors. However, the auxotrophy severely restricts growth of these bacteria in normal tissue enabling them to be used for cancer treatment. The S. ty ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Liquid Array Protein Assay Platform
SBC: ARRAYOMICS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The aim of this project is to develop and optimize our novel particle-based microarray platform, ArrayableESP, for application to high multiplex (50- to 2000-plex) proteomic analysis of human serum samples. ESPs are optically-encoded microfabricated particles that can be manipulated using magnetic force. They are manufactured on commercially available photolith ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Sustained Release Depot Olanzapine
SBC: AURITEC PHARMACEUTICALS, INC. Topic: NIMHDESCRIPTION (provided by applicant): The long-term goal of this research is to minimize morbidity due to non-adherence to outpatient antipsychotic-antimanic therapy with olanzapine. Olanzapine is currently a mainstay of treatment for psychotic disorders and mania. Its elimination half-life of (ca. 30 h in humans) is appropriate for once-daily oral dosing. Most psychotic and manic-depressive disord ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Not Available
SBC: BIOASSAY SYSTEMS, LLC Topic: NCIThe Contractor will develop pharmacodynamic assays for measuring a number of high-priority molecular targets. These assays will be suitable for pre-clinical and clinical testing to allow for rapid evaluation of treatment responses, gauge treatment correspondence to tumor stasis/regression, allow patient stratification for clinical trials and facilitate clinical validation of cancer therapeutics at ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPMENT OF A NANOSECOND PULSED ELECTRIC FIELD SYSTEM TO TREAT SKIN CANCER
SBC: BIOELECTROMED CORPORATION Topic: NCIDESCRIPTION (provided by applicant): BioElectroMed is developing a new medical device called the PulseCure System that utilizes nanosecond pulsed electric fields to eliminate both benign and malignant skin lesions. We have used the PulseCure to treat malignant melanoma and basal cell carcinoma in mice with very high efficacy. With a single, 6-minute treatment using 100 ns pulses, we can trigger co ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Functionally Validated Lentiviral siRNA libraries
SBC: Cellecta, Incorporated Topic: NCRRDESCRIPTION (provided by applicant): Despite rapid advances in elucidating the molecular basis of human diseases, an ostensibly more difficult post-genomic challenge is the functional annotation of disease-specific signaling pathways and integration of this information into the development of novel drugs. RNA interference (RNAi) now makes it possible to use large-scale functional genomic strategie ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Arsenic Selective Ligand-Anchored Fiber for Purification of Drinking Water
SBC: Chemica Technologies, Inc Topic: NIEHSDESCRIPTION (provided by applicant): Today, arsenic (As) poisoning is one of the major environmental threats worldwide as millions of human beings have been exposed to excessive arsenic through contaminated drinking water. The serious toxicity of arsenic has been well documented. Worldwide, communities demand novel separation technologies for the removal of arsenic from drinking water. Conventiona ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Topical adjuvants to enhance the efficacy of influenza vaccines
SBC: LANCELL, LLC Topic: NIAIDDESCRIPTION (provided by applicant): An adequate medical response to the threat of pandemic influenza includes surveillance and isolation, a sufficient supply of effective antiviral drugs, and rapid development of a protective vaccine. Under optimal circumstances, production of enough vaccine to protect the US population would take 6 months. A lag time of 6 months between identification of a pand ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
DRW HIV-Ab/HCV-Ab/HBsAg Triplex Rapid Test Submission for FDA-PMA Approval
SBC: DIAGNOSTICS FOR THE REAL WORLD LIMITED Topic: NHLBIDESCRIPTION (provided by applicant): Confidential information: patent application in process. Diagnostics for the Real World, Ltd. (DRW) aims to market a high-performance triplex rapid test (DRW HIV- Ab/HCV-Ab/HBsAg Triplex Rapid Test; DRW-HTRT), which can simultaneously detect for anti-HIV antibodies (HIV-Ab) for human immunodeficiency virus (HIV), anti-HIV antibodies for hepatitis C virus (HCV) ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health